Literature DB >> 4856053

Stimulators and inhibitors of hepatic porphyrin formation in human sera.

A B Rifkind, S Sassa, I R Merkatz, R Winchester, L Harber, A Kappas.   

Abstract

Human sera were found to contain factors that stimulate and factors that inhibit porphyrin formation by cultured avian liver cells. The capacity of sera to stimulate or inhibit porphyrin formation varied in different hormonal states and in the porphyrias. Sera from 31 post partum women, eight of whom were not lactating, inhibited porphyrin formation to a mean level 30% below the level in control cultures and also inhibited drug and steroid stimulation of porphyrin formation. In contrast, mean porphyrin formation compared to control cultures was increased between 9 and 21% by sera from 52 normal subjects, 16 women on oral contraceptives, and 11 pregnant women. It was increased 193% by sera from nine subjects with acute intermittent porphyria and 172% by sera from 13 subjects with porphyria cutanea tarda. Heated sera or ethanol extracts of sera from all groups of subjects further increased the mean porphyrin stimulation by sera and, for the post partum subjects, eliminated the inhibitory effect. Ethanol extracts of sera from 28 oral contraceptive-treated women caused significantly greater mean stimulation of porphyrin formation than did extracts of sera from 30 normal women. While sera from 17 out of 22 porphyric subjects contained both stimulatory and inhibitory factors, 5 out of 22 had no evidence of an inhibitory component. There appeared to be heterogeneity in the occurrence of the factors among porphyrics.The factor(s) in sera responsible for porphyrin stimulation were heat-stable and insensitive to trypsin; were present in the supernates after ethanol precipitation of plasma proteins; were extractable in ethyl acetate and nondialyzable; and they migrated with the albumincontaining fraction of serum during electrophoresis. The factor(s) responsible for porphyrin inhibition were heat labile, sensitive to trypsin, and resistant to neuraminidase; were present in the ethanol precipitates of sera and were nondialyzable; and they migrated with the gamma globulin fraction of serum during electrophoresis. Inhibition of porphyrin formation was not attributable to heme, free or bound as hemoglobin, hemopexin, or hemalbumin.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4856053      PMCID: PMC333103          DOI: 10.1172/JCI107655

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  HUMORAL CONTROL OF ERYTHROPOIETIC ACTIVITY IN MAN DURING AND AFTER ALTITUDE EXPOSURE.

Authors:  C REYNAFARJE; J RAMOS; J FAURA; D VILLAVICENCIO
Journal:  Proc Soc Exp Biol Med       Date:  1964-07

2.  The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system.

Authors:  J M KISSANE; E ROBINS
Journal:  J Biol Chem       Date:  1958-07       Impact factor: 5.157

3.  Immunological and biological activity of HCG following progressive desialylation.

Authors:  E V Van Hall; J L Vaitukaitis; G T Ross; J W Hickman; G Ashwell
Journal:  Endocrinology       Date:  1971-02       Impact factor: 4.736

4.  Excessive urinary excretion of certain porphyrinogenic steroids in human acute intermittent porphyria.

Authors:  A Goldberg; M R Moore; A D Beattie; P E Hall; J McCallum; J K Grant
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

5.  Behavior of hepatic microsomal cytochromes after treatment of mice with drugs known to disturb porphyrin metabolism in liver.

Authors:  O Wada; Y Yano; G Urata; K Nakao
Journal:  Biochem Pharmacol       Date:  1968-04       Impact factor: 5.858

6.  Drug-induced porphyrin biosynthesis. IV. Investigation of the differences in response of isolated liver cells and the liver of the intact chick embryo to porphyria-inducing drugs.

Authors:  W J Racz; G S Marks
Journal:  Biochem Pharmacol       Date:  1972-01-15       Impact factor: 5.858

7.  Urinary excretion of porphyrin precursors and coproporphyrin in healthy females on oral contraceptives.

Authors:  P Koskelo; A Eisalo; I Toivonen
Journal:  Br Med J       Date:  1966-03-12

8.  Steroid induction of porphyrin synthesis in liver cell culture. I. Structural basis and possible physiological role in the control of heme formation.

Authors:  S Granick; A Kappas
Journal:  J Biol Chem       Date:  1967-10-25       Impact factor: 5.157

9.  The occurrence of substances in human plasma capable of inducing the enzyme delta-aminolevulinate synthetase in liver cells.

Authors:  A Kappas; C S Song; S Sassa; R D Levere; S Granick
Journal:  Proc Natl Acad Sci U S A       Date:  1969-10       Impact factor: 11.205

10.  A radioimmunoassay for human prolactin.

Authors:  P Hwang; H Guyda; H Friesen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

View more
  5 in total

1.  Study of factors causing excess protoporphyrin accumulation in cultured skin fibroblasts from patients with protoporphyria.

Authors:  J R Bloomer; D A Brenner; M J Mahoney
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

2.  Acute intermittent porphyria--an unusual cause of "surgical" abdomen. Response to propranolol therapy.

Authors:  I Srugo; E Said; S Korman; M Jaffe
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

3.  On the obligatory role of the hypophysis in sexual differentiation hepatic metabolism in rats.

Authors:  J A Gustafsson; A Stenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

4.  Differential responses to inducers of delta-aminolaevulinate synthase and haem oxygenase during pregnancy.

Authors:  M K Sardana; S Sassa; A Kappas
Journal:  Biochem J       Date:  1981-08-15       Impact factor: 3.857

5.  Study of the developmental pattern of heme catabolism in liver and the effects of cobalt on cytochrome P-450 and the rate of heme oxidation during the neonatal period.

Authors:  M D Maines; A Kappas
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.